I spoke to Fred for about 10 minutes today. He said the partner is still “engaged” and that there are some “extraneous” things to occur which they do not have control over. He said he didn’t know what the plan was regarding the R/S. The big news though was that they are planning/working to do an uplist and the partnership at the same time. He mentioned the noteholders needing to agree to certain things- (I’m not sure if they have already or not- he wasn’t clear) He said the partner was well established in the wound market.
I assume they would announce the deal and an impending uplist before it would actually close. That would give a little bit of time for the price to adjust upwards to a fair market value and then they would be able to decide what the R/S ratio would be based on where the shares are at. The noteholders would need to agree to come off the floorless terms if this was to work - no doubt for more money. I’d be interested in hearing anyone else’s opinion about this.
(7)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links